Sickle cell anemia, L-glutamine, hydroxyurea, pain crisis. Sickle-cell disorders, Sickle-cell anaemia with crisis, Sickle-cell anaemia without crisis, Double heterozygous sickling disorders, Sickle-cell trait, Other sickle-cell disorders
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: The allocation of two randomized block blinds is encoded in numbered envelopes and is prepared according to the number of samples and will be pr
Sponsors
Boushehr University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with sickle-cell syndrome Age more than five-year-old No other accompanying hematologic diseases All patients should be on Hydroxyurea At least two (extreme) pain crises have been documented in the past year (defining a pain crisis as pain that results from treatment with a drug or injectable ketorolac in the emergency department (ED) (or outpatient treatment center) or during hospitalization. Becomes)
Exclusion criteria
Exclusion criteria: Occurrence of life-threatening events not related to SCD during treatment Patient dissatisfaction with participation in the study Serum albumin levels are less than 3 g / dL Internationally normalized ratios of prothrombin time are higher than 2.0 The treated with L-glutamine within 30 days prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of pain crisis. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Clinical examination by a pediatric hematologist and oncologist.;Number of hospitalizations for pain associated with sickle cell anemia. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Clinical examination by a pediatric hematologist and oncologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of Priapism event. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Clinical examination by a pediatric hematologist and oncologist.;Number of acute chest syndrome. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Clinical examination by a pediatric hematologist and oncologist.;Number of splenic sequestration events. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Clinical examination by a pediatric hematologist and oncologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNader Shakibazad
Boushehr University of Medical Sciences
Outcome results
None listed